04:58 PM EDT, 10/14/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) said late Tuesday it has begun an underwritten public offering of $150 million of its shares.

The firm said it has also granted its underwriters a 30-day option to buy up to $22.5 million additional shares. JPMorgan, Jefferies, Citigroup, and Guggenheim Securities are joint book-runners.

The use of proceeds include to advance the clinical development of its lead product candidate, Duravyu, and for general corporate purposes, EyePoint said.

Shares were over 6% lower in after-hours trading.